ChAd63 CS/ME-TRAP/AMA1(University of Oxford)

This is an open label, multi-centre phase I/IIa sporozoite-challenge trial to assess the safety, immunogenicity and efficacy of two combination ChAd63-MVA heterologous prime-boost vaccination regimens. All volunteers recruited will be healthy, malaria naïve adults aged between 18 and 45 years.
To determine the efficacy of each of two combinations of heterologous prime-boost immunisation strategies:
ChAd63-MVA ME-TRAP combined with ChAd63-MVA CS
ChAd63-MVA ME-TRAP combined with ChAd63-MVA CS and ChAd63-MVA AMA1
The study will be conducted at the University of Oxford's Centre for Clinical Vaccinology and Tropical Medicine (CCVTM), Oxford, UK and the Wellcome Trust Clinical Research Facility in Southampton, UK. The malaria challenge will take place at the insectary at Imperial College (Infection and Immunity Section) in London, UK.